In 1850, Borgo SS Apostoli no. 18 in Florence witnessed the inauguration of a "Grocery and Chemist shop", the initiative of Pietro Malesci. Dr. Malesci was an extremely farsighted research chemist with extraordinary entrepreneurial skills. It was in this very store in fact, that the business enterprise started which has today become the "Istituto Farmacobiologico Malesci" (the Malesci Pharmacobiological Institute), one of the most important fully Italian-owned companies in its field in Italy.

In 1896, Pietro's son Carlo, following in his father's footsteps, inaugurated a "Pharmaceutical Laboratory" next to the old store in Florence. For the next few years this laboratory carried out development and in-depth research of techniques in the production of Galenical preparations and medicinal specialities, including the 'Malesci Hyperbiotin', a tonic that was widely used in Italy and Latin America. Its success, together with the perspicacious choice of concentrating activities on the production of drugs used as a therapy for cardiovascular illnesses, led to the building of new headquarters in Campo di Marte, a suburb of Florence. Unfortunately just as the building was completed it was destroyed in the bombing of September 1943. Production continued in Borgo SS Apostoli and it was during this period that Malesci laid the foundations for achieving market leadership in the field of pneumology, something which it still maintains today in Italy.

The first registration in Italy of a xanthine-based preparation dates back to 1946. This was destined to remain, with all its derivatives, a fundamental drug for the treatment of asthma attacks and broncho-constriction.

In November 1966, the waters that flooded Florence did not spare the Malesci production plants or the research laboratories that had moved near the station of S. Maria Novella, not far from the banks of the River Arno. Thanks to the efforts of the entire workforce, including managers, researchers, office workers and unskilled labour, the Company was quickly back on its feet however and able to continue its business. During this time, apart from consolidating its role as sector leader in areas such as cardiology and pneumatology, Malesci also organised a series of scientific and publishing initiatives, like the magazine "Cardiologia pratica" ('Practical Cardiology') and "Le giornate scientifiche Malesci" ('The Malesci Scientific Days'). The company took out patents and registered several molecules, such as antiarrhythmics and new theophyllines.

In 1978, Malesci joined the Menarini Group, the most important pharmaceutical organization in Italy and on an international level. From the 1980s onwards, Malesci has expanded its own list of high scientific profile molecules belonging to the most widely used pharmacological classes in therapies. Included among these is the highly significant molecule, omeprazole, part of the anti-secretory category and progenitor of a new class of drugs for the treatment of acid-correlated pathologies (proton pump inhibitors). These drugs, which act in the closing stages of gastric secretion, have become the reference point in medical therapy for these illnesses, progressively replacing the more obsolete classes of drugs.

In 2002 Malesci reaches another important goal in gastroenterology, presenting esomeprazole, the first proton pump inhibitor of second generation.
Malesci can also count anti-hypertensive (olmesartan and quinapril), diuretic (torasemide) drugs among its products for the prevention and treatment of the most widespread cardiovascular pathologies, in keeping with its cardiological traditions. Particularly Olmesartan, which is a drug of more recent commercialization, belongs to the innovative class of ABRs, anti-hyperthensive with deep therapeutic qualities. Moreover, antibiotic therapy is one of the most important areas in which Malesci is active, thanks to clarithromycin, used extensively in treating the more common infective illnesses of the upper and lower airways and for eradicating Helicobacter pylori.


 Copyright 2001 Malesci ITALY - All rights reserved